Dr Reddy’s on Wednesday released ‘important’ information regarding COVID-19 drug 2-deoxy-D-glucose (2-DG), which it has developed in collaboration with DRDO, reports ANI. The multinational pharmaceutical company asked people to beware of unverified messages on social media and spurious products sold in the name of the 2-DG drug. 

Also read: How does DRDO’s oral drug for COVID-19, 2-DG, work?

In its notice, Dr Reddy’s stated that 2-DG can be administered only upon prescription. It added that the drug – an ‘add on’ therapy- is yet to be launched in the market and its price has not been announced. 

The commercial launch to government and private hospitals is expected to take place in mid-June, Dr Reddy’s added. 

Also read: IIT alumni? Kejriwal’s Singapore COVID variant comment sparks hilarious reactions

  Union Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday had released the first batch of DRDO’s  2-deoxy-D-glucose drug for COVID-19. The Drugs Controller General of India had approved the drug on May 1. The drug is expected to act as an adjunct therapy for emergency use in moderate to severe COVID-19 cases.